Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWNecrosulfonamide-d4 is intended for use as an internal standard for the quantification of necrosulfonamide by GC- or LC-MS. Necrosulfonamide is an inhibitor of necroptosis, apoptosis, and pyroptosis.1,2 It inhibits IL-8-induced increases in receptor-interacting serine/threonine kinase 1 (RIPK1), RIPK3, mixed lineage kinase domain-like protein (MLKL), caspase-3, and caspase-8 levels, as well as IL-8-induced necroptosis and apoptosis in isolated human nucleus pulposus cells.1 Necrosulfonamide binds to gasdermin D and inhibits NLRP3- and pyrin-mediated pyroptosis in mouse bone marrow-derived macrophages (BMDMs) when used at a concentration of 5 µM.2 In vivo, necrosulfonamide (20 mg/kg) increases survival in a mouse model of LPS-induced sepsis. It also improves motor function and reduces spinal edema in a mouse model of surgically induced spinal cord injury (SCI).3
WARNING This product is not for human or veterinary use.
1. Necrosulfonamide (NSA) protects intervertebral disc degeneration via necroptosis and apoptosis inhibition. Eur. Rev. Med. Pharmacol. Sci. 24(5), 2683-2691 (2020).
2. Chemical disruption of the pyroptotic pore-
3. Necrosulfonamide ameliorates neurological impairment in spinal cord injury by improving antioxidative capacity. Front. Pharmacol. 10, 1538 (2020).